Category:

Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy, a treatment that could cost more than a million dollars, but the gesture comes with strings attached...The Swiss drugmaker wants insurers to commit to coverage for patients identified with the rare and often deadly disease...Novartis also seeks their support for widespread screening to identify newborns with SMA, and to ensure quick authorization for the gene therapy, with the aim of starting treatment within two weeks of diagnosis...The U.S. Food and Drug Administration is due to decide this month on approval for Novartis’ Zolgensma. Novartis, which has made a huge bet on gene therapy for future growth, says the one-time treatment could be a cure for SMA and is pushing for a price in the range of $1.5 million to $5 million. That would make Zolgensma the most expensive new therapy to date...READ MORE

The ePrescription is intended to generate added value for patients in Germany - and to stimulate digitisation in the healthcare market...The ePrescription is to be established in Germany by 2020. In April, German health minister Jens Spahn spoke at the DMEA 2019 (formerly conhIT) in Berlin about its benefits and opportunities in Germany...discussed the...implementation and the added value resulting from ePrescription and other online services for digitising the German healthcare system... The e-recipe will bring real added value. If we combine it with on-line consultations or pharmacy delivery services, the range of services offered to patients will be extended to bring the digital component to healthcare...READ MORE

Jaime Rosenberg, welcome to This Week in Managed Care from the Managed Markets News Network

The company (Intel) says algorithms can simplify trials and accelerate time to market for new drugs...Efforts to implement artificial intelligence, advanced analytics and machine learning could have multiple applications for the healthcare and pharmaceutical industries...The report, “Harnessing AI and Analytics to Drive Digital Transformation,” comes as health systems across the country are working to deploy advanced data analytics to provide faster care for their patients...AI-based algorithms can optimize clinical trial design by eliminating testing criteria that increases time but has a minimal impact on the overall effectiveness of what is being tested...READ MORE

Samantha DiGrande, Welcome to This Week in Managed Care from the Managed Markets News Network

Samantha DiGrande, Welcome to This Week in Managed Care from the Managed Markets News Network

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

In its latest move to rein in what it views as anticompetitive tactics in the healthcare industry, the Federal Trade Commission filed a lawsuit against health information company Surescripts charging the company with illegally monopolizing the e-prescribing market...The FTC alleges that the company employed "illegal vertical and horizontal restraints in order to maintain its monopolies over two e-prescribing markets: routing and eligibility."... Surescripts has maintained at least a 95% share over many years...the FTC said it is seeking to undo and prevent Surescripts’s unfair methods of competition, restore competition, and provide monetary redress to consumers...READ MORE